A5066037666- Colorectal Cancer Screening and Detection
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Head and Neck Cancer Studies
- Cervical Cancer and HPV Research
- Molecular Biology Techniques and Applications
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal and Anal Carcinomas
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Digestive system and related health
- Epigenetics and DNA Methylation
- Tumors and Oncological Cases
- Radiomics and Machine Learning in Medical Imaging
- Gastrointestinal disorders and treatments
- Mycobacterium research and diagnosis
- Global Cancer Incidence and Screening
- Heparin-Induced Thrombocytopenia and Thrombosis
- Healthcare Policy and Management
- Patient Satisfaction in Healthcare
- COVID-19 Clinical Research Studies
- Retinal and Optic Conditions
Exact Sciences (United States)
2014-2023
Medical Technologies (Czechia)
2021
Mayo Clinic
2011-2020
WinnMed
2020
Berger (Canada)
2018
University Hospitals of Cleveland
2017
Military Health System
2017
Case Comprehensive Cancer Center
2017
University of Calgary
2016
Chestnut Hill College
2015
An accurate, noninvasive test could improve the effectiveness of colorectal-cancer screening.We compared a noninvasive, multitarget stool DNA with fecal immunochemical (FIT) in persons at average risk for colorectal cancer. The includes quantitative molecular assays KRAS mutations, aberrant NDRG4 and BMP3 methylation, β-actin, plus hemoglobin immunoassay. Results were generated use logistic-regression algorithm, values 183 or more considered to be positive. FIT than 100 ng per milliliter...
As a noninvasive colorectal cancer (CRC) screening test, multi-marker first generation stool DNA (sDNA V 1.0) test is superior to guaiac-based fecal occult blood tests. An improved sDNA assay (version 2), utilizing only two markers, hypermethylated vimentin gene (hV) and site integrity (DY), demonstrated in training set (phase 1a) an even higher sensitivity (88%) for CRC with specificity of 82%.To validate independent patients 1b) the version 2 CRC.Forty-two 241 subjects normal colonoscopy...
Serrated polyps of the colorectum are a histologically and genetically heterogeneous group lesions, which include classic hyperplasic polyps, sessile serrated adenomas (SSAs), traditional adenomas. Accumulating evidence suggests that they may have different malignancy potentials. This study sought to determine association between presence large colorectal synchronous advanced neoplasia.Among 4,714 asymptomatic subjects who underwent screening colonoscopy, cases neoplasia (tubular adenoma >...
The NavDx® blood test analyzes tumor tissue modified viral (TTMV)-HPV DNA to provide a reliable means of detecting and monitoring HPV-driven cancers. has been clinically validated in large number independent studies integrated into clinical practice by over 1000 healthcare providers at 400 medical sites the US. This Clinical Laboratory Improvement Amendments (CLIA), high complexity laboratory developed test, also accredited College American Pathologists (CAP) New York State Department...
Abstract Purpose: Human papillomavirus (HPV) is causally linked to oropharyngeal squamous cell carcinoma (OPSCC). Consensus guidelines recommend clinical exams and imaging in decreasing frequency as part of posttreatment surveillance for recurrence. Plasma tumor tissue modified viral (TTMV)-HPV DNA testing has emerged a biomarker which can inform disease status during surveillance. Experimental Design: This retrospective observational cohort study involved 543 patients who completed...
INTRODUCTION: We set out to evaluate the performance of a multitarget stool DNA (MT-sDNA) in an average-risk colonoscopy-controlled colorectal cancer (CRC) screening population. MT-sDNA test results were evaluated against fecal immunochemical (FIT) for detection different lesions, including molecularly defined high-risk adenomas and several other tumor characteristics. METHODS: Whole samples (n = 1,047) prospectively collected subjected test, which tests KRAS mutations, NDRG4 BMP3 promoter...
Precursors to 1/3 of colorectal cancer (CRC), serrated polyps have been under-detected by screening due their inconspicuous, non-hemorrhagic, and proximal nature. A new multi-target stool DNA test (multi-target sDNA) shows high sensitivity for both CRC advanced adenomas. Screen detection this approach requires further validation. We sought assess compare noninvasive sessile (SSP) ≥ 1 cm sDNA an occult blood fecal immunochemical (FIT).In a blinded prospective study, single sample used tests...
Objective To determine cross-sectional adherence with the multi-target stool DNA test used for colorectal cancer screening in a large, fully insured Medicare population. Methods All patients aged 65–85 valid order from 1 September 2016 to 31 August 2017 identified Exact Sciences Laboratories (Madison, WI; sole-source national provider) database were evaluated adherence. Cross-sectional adherence, defined as completion within 365 days date, was analyzed overall and by time well available...
Abstract High-specificity colorectal cancer screening is desirable to triage patients <50 years for colonoscopy; however, most endorsed tests have not been rigorously evaluated in younger populations. This prospective cross-sectional study determined the specificity of multitarget stool DNA (mt-sDNA) test an average-risk population 45 49 year-olds. Specificity was primary outcome and measured participants without or advanced precancerous lesions [APL– adenomas (AA), sessile serrated...
The authors compared the accuracy of conventionally prepared smears and by an automated, fluid-based, thin-layer processing device in detection cytologic abnormalities. A total 3218 patients from five centers took part this study, which a single cervical sample was split into matched pair. conventional smear made routine fashion; remainder cells on sampling were rinsed transport-fixation fluid. slide then solution using processor. Diagnostic findings identified two preparations blinded...
AIMTo determine the uptake of noninvasive multitarget stool DNA (mt-sDNA) in a cohort colorectal cancer (CRC) screening non-compliant average-risk Medicare patients. METHODSThis cross sectional primary care office-based study examined mt-sDNA routine clinical practice among 393 patients ages 50-85 ordered by 77 physicians multispecialty group (USMD Physician Services, Dallas, TX) from October,
A multitarget stool DNA (mt-sDNA) test was recently approved for colorectal cancer (CRC) screening men and women, aged ≥ 50 years, at average risk of CRC. The guidelines currently recommend a 3-year interval mt-sDNA testing in the absence empirical data. We used clinical effectiveness modeling to project decreases CRC incidence related mortality associated with help inform setting.The Archimedes model (Archimedes Inc., San Francisco, CA) conduct 5-arm, virtual, study population 200,000...
BACKGROUND Multitarget stool DNA (mt‐sDNA) is an approved method for colon cancer screening that especially relevant patients who cannot undergo colonoscopy. Although the test performance has been evaluated in a large clinical trial, it was limited to predominantly white population. Given differences epidemiology and biology of African American individuals, authors sought compare mt‐sDNA between racial groups. METHODS The prospectively identified aged ≥40 years were referred colonoscopy at...
OBJECTIVES: Multitarget stool DNA (MT-sDNA) testing has grown as a noninvasive screening modality for colorectal cancer (CRC), but real-world clinical data are limited in the post-FDA approval setting. The effect of previous colonoscopy on MT-sDNA performance is not known. We aimed to evaluate findings neoplasia (CRN) at diagnostic patients with positive testing, stratified by patient exposure colonoscopy. METHODS: identified consecutive completing over 39-month period and reviewed records...
Background & AimsWe aimed to compare the incidence of aerodigestive cancers in persons with negative results from colonoscopies and positive vs multitarget stool DNA tests for colorectal cancer expected incidence.MethodsWe performed a retrospective cohort study 1216 subjects comprehensive patient records and/or registry data 3 medical centers North America. Subjects had no neoplasia or only nonadvanced adenomas, based on screening colonoscopy, either (concordant n = 1011) (discordant 205)...